688235:SHA
BeOne Medicines AG
256,79 CNY
arrow_upward
+0,32%(+0,81) 1 d
19 okt., 10:24:57 GMT+8 · CNY
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för 688235 …
Öppen
253,00 CNY
Högt
261,00 CNY
Lågt
253,00 CNY
Börsvärde
303,26 md
Genomsn. vol.
2,93 mn
Volym
1,44 mn
P/E-tal
91,71
52v högst
319,24 CNY
52v lägst
205,51 CNY
EPS
2,80 CNY
Antal anställda
12 tn
Öppen
253,00 CNY
Högt
261,00 CNY
Lågt
253,00 CNY
Börsvärde
303,26 md
Genomsn. vol.
2,93 mn
Volym
1,44 mn
P/E-tal
91,71
52v högst
319,24 CNY
52v lägst
205,51 CNY
EPS
2,80 CNY
Antal anställda
12 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
ad-hoc-news.de
·
för 1 dag sedan
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
MarketBeat
·
för 3 dagar sedan
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Om BeOne Medicines AG
VdJohn Vincent Oyler | John Vincent Oyler
Anställda12 tn
Grundades28 okt. 2010
Huvudkontor-
Sektor-
Webbplatsbeonemedicines.com